Drug Discovery Featured Articles & Applications

41. These Are The Top Priorities & Challenges For New CDER Director Patrizia Cavazzoni, M.D. 7/30/2021

    Recently appointed to the permanent CDER director role, Dr. Cavazzoni’s appointment was not unexpected, as she was recruited to join the FDA in 2018 from a senior industry role and served as acting CDER director at the start of the agency’s pandemic response. Her experience suggests she will continue to evolve – rather than revolutionize – FDA’s drug review policies.

42. 10 Critical Validation Parameters For Microbiological Experiments 7/26/2021

    In studying a microbiological method, different validation parameters require assessment. These are variables or factors that can be controlled, changed, or measured in the experiment. This article outlines the key parameters to consider.

43. Emerging Biopharma: Your Next 2 Geographic Markets To Tackle After The US 7/7/2021

    While the majority of the world’s drug development and innovation are underwritten by the United States, emerging drug developers should not overlook these two major regions of the world that represent volume, profit, ingenuity, and growth. 

44. Cell & Gene Therapies For Parkinson’s Disease 7/6/2021

    Emile Nuwaysir, President and CEO of BlueRock Therapeutics explains the recruitment process for the trial, the trial’s primary objective, and more.

45. Biologics Discovery: Picking Winners & Losers 6/18/2021

    Glympse Bio is developing bio-engineered, in-vivo diagnostic technologies that could offer biologics developers earlier insight into target engagement and therapeutic response. That spells big implications on translational research, speed to clinic, and time to market.

46. Five Maxims For Outsourcing Success 6/8/2021

    "Outsourcing is really about positioning your CDMO to your competitive advantage," says Lis Wyman of Acceleron Pharma. That might just be the "maximum maxim" for outsourcing strategy. But Wyman has four more to offer, all enlightening to your craft of drug development and manufacturing.

47. The Potential And Future Of Cell Therapy 4/22/2021

    While the field has made laudable progress in developing novel biomolecules that can be used to control cell function (e.g. mRNA, DNA, CRISPR, siRNA, proteins, peptides, etc.), very little progress has been made on reliably delivering these materials to a cell and enabling robust engineering of cell function without significantly impairing cell health. 

48. Tevogen Bio, BioCentriq Team Up To Manufacture T-Cell Therapy For COVID-19 3/23/2021

    Tevogen Bio recently announced its partnership with BioCentriq, a New Jersey-based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment. 

49. How Computational Drug Discovery Is Disrupting Biopharma 3/12/2021

    NeuBase Therapeutics CEO Dr. Dietrich Stephan discusses the important role computational drug discovery plays as we emerge from what he characterizes as “a decades-long, multi-billion-dollar chemical engineering escapade with a very low success rate to find one drug.”

50. Inside Omega Therapeutics’ Epigenomic Controllers™ 12/1/2020

    Omega Therapeutics is developing novel engineered and modular therapeutics, called Omega Epigenomic Controllers™, that are designed to target with high specificity and downregulate or upregulate the level of expression of any of the 25,000+ human genes, individually or collectively, with controlled durability, to treat and potentially cure disease.